This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/521635-janssen-covid-vaccine-resuming-europe-rollout/
The article has changed 4 times. There is an RSS feed of changes available.
| Version 2 | Version 3 |
|---|---|
| Shipments of J&J Covid-19 vaccine to resume in Europe, company says after EU regulator finds benefits outweigh blood clot risks | Shipments of J&J Covid-19 vaccine to resume in Europe, company says after EU regulator finds benefits outweigh blood clot risks |
| (4 months later) | |
| Johnson & Johnson has said it will resume delivery of its Covid-19 vaccine to the EU after the bloc's regulator, the European Medicines Agency's (EMA), said the benefits of the jab outweigh any risks despite blood clot concerns. | Johnson & Johnson has said it will resume delivery of its Covid-19 vaccine to the EU after the bloc's regulator, the European Medicines Agency's (EMA), said the benefits of the jab outweigh any risks despite blood clot concerns. |
| On Tuesday, the EMA said a review of the Janssen vaccine by its safety committee had found that unusual blood clots with low blood platelets should be listed as "very rare side effects" of the jab and included in the product information. | On Tuesday, the EMA said a review of the Janssen vaccine by its safety committee had found that unusual blood clots with low blood platelets should be listed as "very rare side effects" of the jab and included in the product information. |
| The agency also said the overall benefit-risk balance of the jab "remains positive" after the committee's review of eight reported blood clots – one of which was fatal – from among the 7 million doses administered in the US. | The agency also said the overall benefit-risk balance of the jab "remains positive" after the committee's review of eight reported blood clots – one of which was fatal – from among the 7 million doses administered in the US. |
| Following the announcement, Johnson & Johnson confirmed in a statement that it would resume deliveries of the single-shot vaccine to the EU, Norway and Iceland. | Following the announcement, Johnson & Johnson confirmed in a statement that it would resume deliveries of the single-shot vaccine to the EU, Norway and Iceland. |
| The company had announced last week it would delay its European rollout following the suspension of its use in the US. | The company had announced last week it would delay its European rollout following the suspension of its use in the US. |
| The American drug maker's chief scientific officer, Paul Stoffels, said the company "appreciates the rigorous review" of the EMA. | The American drug maker's chief scientific officer, Paul Stoffels, said the company "appreciates the rigorous review" of the EMA. |
| Dutch Health Minister Hugo de Jonge confirmed that the Netherlands would resume its rollout of the Janssen vaccine on Wednesday following the EMA's review, saying that the jab "can be used as planned." | Dutch Health Minister Hugo de Jonge confirmed that the Netherlands would resume its rollout of the Janssen vaccine on Wednesday following the EMA's review, saying that the jab "can be used as planned." |
| Italy’s health ministry has also recommended using the Janssen vaccine, but only for those aged 60 and over due to the potentially higher risk of blood clots among younger cohorts. | Italy’s health ministry has also recommended using the Janssen vaccine, but only for those aged 60 and over due to the potentially higher risk of blood clots among younger cohorts. |
| Last week, the US announced it would pause its deployment of the vaccine after six women under the age of 50 who had received it suffered serious blood clots. | Last week, the US announced it would pause its deployment of the vaccine after six women under the age of 50 who had received it suffered serious blood clots. |
| Authorities there are set to convene on Friday to discuss resuming its use. | Authorities there are set to convene on Friday to discuss resuming its use. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |